Digitisation | August 10, 2021
Fulgent Genetics and Helio Health partners to commercialize early cancer detection tests
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
The goal for the project is the identification and optimization of anti-viral compounds.
Filing for WHO Emergency Use Authorisation this month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Deal for 100 million doses with additional 100 million through 2023
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
Subscribe To Our Newsletter & Stay Updated
